Omidenepag isopropyl noninferior to latanoprost for ocular hypertension, glaucoma
29 Jan 2021
byAudrey Abella
The ocular hypotensive agent omidenepag isopropyl (OMDI) was noninferior to the current standard of care, latanoprost, in reducing intraocular pressure (IOP) in individuals with ocular hypertension (OHT) or primary open-angle glaucoma, results of the phase III AYAME study have shown.
Omidenepag isopropyl noninferior to latanoprost for ocular hypertension, glaucoma
29 Jan 2021